HC Wainwright & Co. Reaffirms Buy Rating for Avalo Therapeutics, Increases Price Target to $25

Written by Emily J. Thompson, Senior Investment Analyst

AVTX+1.87%

Source: Benzinga

Updated: Sep 17 2025

0mins

Source: Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like AVTX with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

AVTX

$15.25+Infinity%1D

Analyst Views on AVTX

Wall Street analysts forecast AVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTX is 38.00 USD with a low forecast of 25.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 14.970

Low

25.00

Averages

38.00

High

48.00

Current: 14.970

Low

25.00

Averages

38.00

High

48.00

Mizuho

Joseph Catanzaro

Outperform

initiated

$39

2025-12-17

Reason

Mizuho

Joseph Catanzaro

Price Target

$39

AI Analysis

2025-12-17

initiated

Outperform

Reason

Mizuho analyst Joseph Catanzaro initiated coverage of Avalo Therapeutics with an Outperform rating and $39 price target. The firm believes the company's lead program AVTX-009 is well positioned for a positive Phase II readout in hidradenitis suppurativa in mid-2026. It projects $1B in risk-adjusted 2035 worldwide sales for AVTX-009 and expects positive Phase II data to drive share outperformance.

Oppenheimer

Outperform

maintain

$35

2025-09-15

Reason

Oppenheimer

Price Target

$35

2025-09-15

maintain

Outperform

Reason

Oppenheimer recommends investors to be buyers of Avalo Therapeutics in anticipation of the presentation of lutikizumab's open-label Phase 2 data in about 40 treatment-naive hidradenitis suppurativa patients late this week. The firm, which forecasts \"strong results for luti\" at the EADV conference given its substantial benefit previously shown in a difficult-to-treat, TNF-refractory disease population, would expect '009 - with its multiple advantages over luti - to show \"at least as good as, and potentially better, efficacy\" when LOTUS reads out in mid-2026, says the analyst. The firm has an Outperform rating and $35 price target on Avalo shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AVTX

Unlock Now

About AVTX

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for AVTX?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy AVTX?

Get Started Free

Top News

HC Wainwright & Co. Reaffirms Buy Rating for Avalo Therapeutics, Increases Price Target to $25

Get Free Real-Time Notifications for Any Stock

Analyst Views on AVTX

About AVTX

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Analysis of Declining Stocks: C3.ai and The Trade Desk

Las Vegas Sands Earnings Report Triggers Stock Plunge

Valvoline Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations

Avalo Therapeutics Reveals Inducement Grants for New Hires in Accordance with Nasdaq Listing Rule 5635(c)(4)

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch